Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be \>=18 years of age;~* The patients must be Operable primary invasive breast cancer;~* Definitive loco-regional surgery must be completed;~* Primary tumor centrally confirmed as triple negative;~* Operable node-positive (or node-negative with tumor diameter ≥ 0.5cm);~* Chest, abdominal, bone imaging performed with 3 months prior to randomization must not reveal the presence of distant spread;~* There are normal organ function, including bone marrow function, renal function, liver function, and cardiac function;~* All patients must have signed and dated an informed consent form.~Exclusion Criteria:~* Patients with bilateral breast cancer, inflammatory carcinomas;~* Patients with positive supraclavicular or internal mammary lymph node;~* Previous breast cancer history;~* Any previous malignancy exceptions for carcinoma of the cervix, squamous carcinoma of the skin, or basal cell carcinoma of the skin;~* Pregnant or breast-feeding women;~* Women who are unwilling to agree to use an effective non-hormonal method of contraception during the treatment period of Xeloda;~* Any sex hormonal therapy;~* Malabsorption syndrome.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Capecitabine (Type: EXPERIMENTAL): Capecitabine 650 mg/m2 bid
- Standard treatment (Type: NO_INTERVENTION): Treatment according to National Comprehensive Cancer Network (NCCN) guideline.

Based on this trial design, predict the completion outcome and termination type (if applicable).